ProKidney Corp.

ProKidney Corp. is a United States based startup focusing on the Health Care and Health and Wellness industries. Established in 2015, it has made significant strides in the treatment of Chronic Kidney Disease (CKD) through innovative cellular therapy. Their lead product candidate, REACT™ (Renal Autologous Cell Therapy), has garnered attention as a first-of-its-kind, patented disease-modifying autologous cellular therapy that exhibits potential to not only slow and stabilize the progression of CKD but also potentially drive meaningful improvement in kidney function, particularly targeting late-stage CKD, stage 3b - 4.

With a decade of research backing its foundation, ProKidney Corp. has achieved milestones such as receiving the Regenerative Medicine Advanced Therapy (RMAT) designation and obtaining guidance from the FDA and EMA for its ongoing Phase 3 clinical program, which commenced in January 2022. The company's recent $140.00M Post-IPO Equity investment as of 11 June 2024 signifies continued support for its groundbreaking work.

For individuals interested in learning more about ProKidney Corp. and its innovative approach, they can visit the official website at www.prokidney.com. The strides made by this startup have the potential to revolutionize the treatment and prevention of CKD, presenting an opportunity for investors seeking impactful ventures in the healthcare sector.